Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
概览
- 阶段
- 2 期
- 干预措施
- 18F-NaF
- 疾病 / 适应症
- Metastatic Prostate Cancer
- 发起方
- National Cancer Institute (NCI)
- 入组人数
- 96
- 试验地点
- 1
- 主要终点
- Accuracy of DCFPyL-PET/CT diagnostics
- 状态
- 进行中（未招募）
- 最后更新
- 26天前
概览
简要总结
Background:
Prostate cancer is the second leading cause of cancer deaths in American men. Few options exist to create images of this type of cancer. Researchers think an experimental radiotracer called 18F-DCFPyL could find sites of cancer in the body.
Objective:
To see if 18F-DCFPyL can identify sites of prostate cancer in people with the disease.
Eligibility:
People ages 18 and older who have metastatic prostate cancer
Design:
Participants will be screened with:
- Blood tests
- Physical exam
- Medical history
Participants will be assigned to 1 of 2 groups based on their PSA.
Participants will have 18F-DCFPyL injected into a vein. About 2 hours later they will have a whole-body Positron Emission
Tomography/Computed Tomography (PET/CT). For the scan, they will lie on their back on the scanner table while it takes pictures of the body. This lasts about 50 minutes.
On another day, participants will have 18F -NaF injected into a vein. About 1 hour later, they will have a whole-body PET/CT.
Participants will be contacted 1 3 days later for follow-up. They may undergo PET/Magnetic Resonance Imaging (MRI) either after having a 18F-DCFPyL PET/CT, or in place of PET/CT imaging. A tube may be placed in the rectum. More coils may be wrapped around the outside of the pelvis.
If the 18F-DCFPyL PET/CT is positive participants will be encouraged to undergo a biopsy of one of the tumors. The biopsy will be taken through a needle put through the skin into the tumor.
Participants will be followed for 1 year. During this time researchers will collect information about their prostate cancer, such as PSA levels and biopsy results.
About 4-6 months after scanning is completed, participants may have a tumor biopsy. The biopsy will be taken through a needle put through the skin into the tumor.
...
详细描述
Background: The objective of this study is to evaluate a radiolabeled urea-based small molecule inhibitor of prostate-specific membrane antigen (PSMA), \[18F\] DCFPyL (DCFPyL) PET/CT (or PET/MRI imaging if available) for detection of metastatic prostate cancer PSMA is a well characterized histological marker of prostate cancer tumor aggressiveness and metastatic potential Our preliminary first-in-human studies demonstrate high specific uptake of a first generation less avid compound, DCFBC, in metastatic prostate cancer and demonstrated feasibility for prostate cancer metastatic detection. We propose to assess the ability of DCFPyL PET to detect metastatic prostate cancer by visual qualitative and quantitative SUV analysis. Correlation will be made to sites of suspected bony metastatic disease detected by ultra-sensitive but less specific \[18F\] Sodium Fluoride (NaF)-PET/CT imaging and all sites of suspected disease detected by \[18F\] Fluorodeoxyglucose (FDG) for prostate cancer. Objective: To compare the diagnostic sensitivity of DCFPyL-PET/CT (or PET/MRI imaging if available) to NaF-PET/CT for detection of prostate cancer bone metastasis based on comparison to reference standard of care conventional imaging modalities (CIM); such as CT and whole body bone scintigraphy incorporating prior and follow-up scans and histopathology when available. Eligibility: Histological confirmation of prostate cancer Age \>=18 years old Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2. Patients must have either: * Confirmation of prostate cancer with identifiable metastatic disease on at least 1 clinically indicated imaging modality. If there is only soft tissue metastasis, one lesion must measure at least 6 mm or greater. OR * Documented history of metastatic prostate cancer. Design: Two Cohort study Cohort 1: Stable/Decreasing Prostate Specific Antigen (PSA): PSA must be equal to or less than 0.5 ng/mL value of the last PSA obtained (at least one month apart) Cohort 2: Rising PSA: PSA must be greater than 0.5 ng/mL above the last PSA value obtained on at least two occasions within 1 year Patients will undergo DCFPyL PET/CT (or PET/MRI), NaF-PET/CT, and FDG PET/CT within 21 days of each other. The order obtained does not matter. The DCFPyL PET/CT (or PET/MRI) will be compared with the NaF-PET/CT and FDG PET/CT and standard chest/abdomen/pelvis CT. DCFPyL PET/CT (or PET/MRI) detection of metastatic disease will be assessed by visual qualitative assessment as positive, equivocal, or negative. Sites of equivocal or positive metastatic disease will have a quantitative PET assessment (SUVmax, SUVmean). A mandatory research biopsy will be performed under image guidance on a suspicious lesion, if feasible. The patients will be followed yearly for 4 years by chart review, phone-call, email or any other NIH approved platform for PSA relapse and radiologic evidence of metastatic disease. Additional 18F-DCFPyL and 18F-FDG PET/CTs might be performed during the subject s follow up period there has been a considerable change in patient status (progression or response) based on PSA value, symptomatology, bone scan or CT findings.
研究者
入排标准
入选标准
- •INCLUSION CRITERIA:
- •Age greater than or equal to 18 years old
- •Eastern Cooperative Oncology Group (ECOG) performance score of 0 to
- •Ability of subject to understand and the willingness to sign a written informed consent document.
- •Patients must have confirmation of prostate cancer with identifiable metastatic disease on at least 1 clinically indicated imaging modality. If there is only soft tissue metastasis, one lesion must measure at least 6 mm or greater. OR Documented history of metastatic prostate cancer.
- •Patients must be co-enrolled on a UOB, GMB or ROB protocol
- •Histological confirmation of prostate cancer
- •Patients must be willing to undergo mandatory research biopsy
排除标准
- •Subjects for whom participating would significantly delay the scheduled standard of care therapy.
- •Subjects with any coexisting medical or psychiatric condition that is likely to interfere with study procedures and/or results.
- •Subjects with severe claustrophobia unresponsive to oral anxiolytics
- •Other medical conditions deemed by the principal investigator (or associates) to make the subject unsafe/ineligible for protocol procedures.
- •Subjects weighing greater than 350 lbs. (weight limit for scanner table), or unable to fit within the imaging gantry
- •Serum creatinine greater than 2 times the upper limit of normal
研究组 & 干预措施
1/Experimental intervention
18F-DCFPyL is administered to cohorts
干预措施: 18F-NaF
1/Experimental intervention
18F-DCFPyL is administered to cohorts
干预措施: 18F-DCFPyL
1/Experimental intervention
18F-DCFPyL is administered to cohorts
干预措施: 18F-FDG
结局指标
主要结局
Accuracy of DCFPyL-PET/CT diagnostics
时间窗: 36 months
Accuracy of DCFPyL-PET/CT diagnostics
次要结局
- PSMA expression in lesion samples from patients with presumed stable disease and actively expanding disease(36 months)
- Association between PSA parameters and the number of metastases identified with DCFPyL- PET/CT (or PET/MRI imaging if available).(36 months)